Harrow Inc. (HROW), an eyecare pharmaceutical company, Thursday said ImprimisRx, a unit of Harrow, has won the trademark infringement case against OSRX, Inc. and its related party Ocular Science, Inc.
ImprimisRx had alleged trademark infringement against OSRX and Ocular Science.
The $34.9 million verdict by the United States District Court for the Southern District of California includes $20.4 million in punitive damages and $14.5 million in actual damages.
The court observed that OSRX, or Ocular Science willfully engaged in trademark infringement.
For comments and feedback: editorial@rttnews.com